RenovoRx (RNXT) Cash from Investing Activities (2022 - 2026)

RenovoRx (RNXT) posted Cash from Investing Activities of -$2000.0 for Q1 2025, down 100.1% sequentially from $2.0 million in Q1 2023.

RenovoRx (RNXT) Cash from Investing Activities (2022 - 2026) Analysis & Trends

RenovoRx has reported Cash from Investing Activities for 3 years, with the latest figure at -$2000.0 in Q1 2025.

Quarterly Cash from Investing Activities changed N/A year-over-year to -$2000.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was -$2000.0 (changed N/A YoY) and the FY2025 annual result came in at -$2000.0, up 83.33% from the prior year.
Cash from Investing Activities eased to -$2000.0 in Q1 2025 per RNXT's latest filing, from $2.0 million in the prior quarter.
Over five years, Cash from Investing Activities peaked at $3.0 million in Q3 2022 and troughed at -$2000.0 in Q1 2025.
A 3-year average of $2.0 million and a median of $2.5 million in 2022 frame the typical range for Cash from Investing Activities.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Investing Activities (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-45.80 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-92.70 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	329.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-49.35 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-363.46 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-3.17 Bn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	24.51 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-229.72 Mn
10	RenovoRx	62.20 Mn	62.20 Mn	766,000.00	-71,000.00

Download Data